Exploring the “Lore of Nutrition”

For the last few days, my Kindle has been my closest companion. “What are you reading”? my wife asked. “I’m reading Lore of Nutrition.” “Ooh, I was sure it was a thriller or one of your crime stories.” In fact, she was right. Although Lore of Nutrition is a book about nutrition, it reads like … Read more

Muscular Strength and Longevity – The Role of Strength Training

In 1953, British researchers discovered that drivers of London’s double-decker buses were more likely to suffer a deadly heart attack than the more physically active conductors (1). Another study published five years later found that the risk of heart attack was higher among government clerks than postmen (2). These studies laid the foundation for the hypothesis … Read more

The CANTOS Trial – Is Targeting Inflammation the Solution to Heart Disease?

The recently published results of the long awaited CANTOS trial may forever change our approach to the prevention and treatment of coronary artery disease (1). Inescapably, there is now proof that targeting inflammation, in this case by a drug, significantly improves outcome for certain very high-risk patients. But, as so often in clinical research, things … Read more

Carbs, Fats and Heart Disease – Time For a Reappraisal Following the PURE Study

Recently many of us were provided an opportunity to watch a highly interesting video on the internet covering a talk given by Dr. Salim Yusuf at a recent Cardiology Update meeting. Dr. Yusuf is the Marion W. Burke Chair in Cardiovascular Disease at McMaster University Medical School in Hamilton, Ontario, Canada and current President of … Read more

The FOURIER Trial – Are We Entering a New Era in Cardiovascular Medicine?

The results of the recently completed FOURIER trial suggest that we have taken a huge step forward in the pharmacological therapy atherosclerotic cardiovascular disease (ASCVD). On February 2, 2017 the biotechnological company Amgen announced that the FOURIER trial evaluating whether the drug evolocumab (Repatha) reduces the risk of cardiovascular events in patients with clinically evident ASCVD … Read more